HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ivanka Trump, Untouchable Launch; Celeb Scents Still Providing A “Pop”

This article was originally published in The Rose Sheet

Executive Summary

Although likely not the next Justin Bieber Someday, new celebrity scents from Parlux and Avon could be “good basic money makers,” according to The NPD Group’s VP and Senior Global Beauty Analyst Karen Grant.

You may also be interested in...



Industry Vets Launch Boutique Fragrance Firm; Miss Universe Is First Client

The Miss Universe Organization is first to sign a licensing agreement with fragrance marketer and distributor Omni Scents, founded by former Parlux Fragrances CEO Neil Katz. Firm looks forward to launching three scents under the deal in August, noting that approximately 1 billion people in 190 countries tuned in to the 2012 Miss Universe pageant.

Parlux Rolls Out First Celeb Scents Since Perfumania Merger

New fragrances from Paris Hilton and Jessica Simpson are the first to emerge from Parlux since Bellport, N.Y.-based Perfumania completed its $118 million acquisition of the firm in April.

Parlux Has “Enough" Celeb Fragrances, Says CEO, Reaffirming New Direction

Still reeling from the loss of the Guess fragrance license, which contributed to a 37% decline in sales for the third quarter, and in light of recent frustrations surrounding the launch of Reb'l Fleur by Rihanna, Parlux Fragrances CEO Frederick E. Purches maintains that it’s time for the company to change direction.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel